1887

Abstract

The majority of infections, including those caused by respiratory syncytial virus (RSV), occur at mucosal surfaces. As no RSV vaccine is available our goal is to produce an effective subunit vaccine with an adjuvant suitable for mucosal delivery and cross-presentation. A truncated secreted version of the RSV fusion (ΔF) protein formulated with polyI : C, an innate defence regulator peptide and polyphosphazene, induced local and systemic immunity, including affinity maturation of RSV F-specific IgG, IgA and virus-neutralizing antibodies, and F-specific CD8 T-cells in the lung, when delivered intranasally. Furthermore, this ΔF protein formulation promoted the production of CD8 central memory T-cells in the mediastinal lymph nodes and provided protection from RSV challenge. Formulation of ΔF protein with this adjuvant combination enhanced uptake by lung dendritic cells and trafficking to the draining lymph nodes. The ΔF protein formulation was confirmed to be highly efficacious and safe in cotton rats.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.058461-0
2014-02-01
2019-09-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/2/301.html?itemId=/content/journal/jgv/10.1099/vir.0.058461-0&mimeType=html&fmt=ahah

References

  1. Andrianov A. K., Marin A., Roberts B. E.. ( 2005; ). Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. . Biomacromolecules 6:, 1375–1379. [CrossRef] [PubMed]
    [Google Scholar]
  2. Andrianov A. K., DeCollibus D. P., Gillis H. A., Kha H. H., Marin A., Prausnitz M. R., Babiuk L. A., Townsend H., Mutwiri G.. ( 2009; ). Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. . Proc Natl Acad Sci U S A 106:, 18936–18941. [CrossRef] [PubMed]
    [Google Scholar]
  3. Bowdish D. M. E., Davidson D. J., Scott M. G., Hancock R. E. W.. ( 2005; ). Immunomodulatory activities of small host defense peptides. . Antimicrob Agents Chemother 49:, 1727–1732. [CrossRef] [PubMed]
    [Google Scholar]
  4. Castiglioni P., Gerloni M., Zanetti M.. ( 2004; ). Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T cells. . Vaccine 23:, 699–708. [CrossRef] [PubMed]
    [Google Scholar]
  5. Collins P. L., Graham B. S.. ( 2008; ). Viral and host factors in human respiratory syncytial virus pathogenesis. . J Virol 82:, 2040–2055. [CrossRef] [PubMed]
    [Google Scholar]
  6. Delgado M. F., Coviello S., Monsalvo A. C., Melendi G. A., Hernandez J. Z., Batalle J. P., Diaz L., Trento A., Chang H. Y.. & other authors ( 2009; ). Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. . Nat Med 15:, 34–41. [CrossRef] [PubMed]
    [Google Scholar]
  7. Falsey A. R., Hennessey P. A., Formica M. A., Cox C., Walsh E. E.. ( 2005; ). Respiratory syncytial virus infection in elderly and high-risk adults. . N Engl J Med 352:, 1749–1759. [CrossRef] [PubMed]
    [Google Scholar]
  8. Garlapati S., Garg R., Brownlie R., Latimer L., Simko E., Hancock R. E. W., Babiuk L. A., Gerdts V., Potter A., van Drunen Littel-van den Hurk S.. ( 2012; ). Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. . Vaccine 30:, 5206–5214. [CrossRef] [PubMed]
    [Google Scholar]
  9. GeurtsvanKessel C. H., Willart M. A. M., van Rijt L. S., Muskens F., Kool M., Baas C., Thielemans K., Bennett C., Clausen B. E.. & other authors ( 2008; ). Clearance of influenza virus from the lung depends on migratory langerin+CD11b but not plasmacytoid dendritic cells. . J Exp Med 205:, 1621–1634. [CrossRef] [PubMed]
    [Google Scholar]
  10. Graham B. S.. ( 2011; ). Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. . Immunol Rev 239:, 149–166. [CrossRef] [PubMed]
    [Google Scholar]
  11. Hancock R. E. W., Sahl H.-G.. ( 2006; ). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. . Nat Biotechnol 24:, 1551–1557. [CrossRef] [PubMed]
    [Google Scholar]
  12. Impact–RSV Study Group ( 1998; ). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. . Pediatrics 102:, 531–537. [CrossRef]
    [Google Scholar]
  13. Jakubzick C., Helft J., Kaplan T. J., Randolph G. J.. ( 2008; ). Optimization of methods to study pulmonary dendritic cell migration reveals distinct capacities of DC subsets to acquire soluble versus particulate antigen. . J Immunol Methods 337:, 121–131. [CrossRef] [PubMed]
    [Google Scholar]
  14. Kim H. W., Canchola J. G., Brandt C. D., Pyles G., Chanock R. M., Jensen K., Parrott R. H.. ( 1969; ). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. . Am J Epidemiol 89:, 422–434.[PubMed]
    [Google Scholar]
  15. Kovacs-Nolan J., Latimer L., Landi A., Jenssen H., Hancock R. E., Babiuk L. A., van Drunen Littel-van den Hurk S.. ( 2009a; ). The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. . Vaccine 27:, 2055–2064. [CrossRef] [PubMed]
    [Google Scholar]
  16. Kovacs-Nolan J., Mapletoft J. W., Lawman Z., Babiuk L. A., van Drunen Littel-van den Hurk S.. ( 2009b; ). Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice. . J Gen Virol 90:, 1892–1905. [CrossRef] [PubMed]
    [Google Scholar]
  17. Lee S., Stokes K. L., Currier M. G., Sakamoto K., Lukacs N. W., Celis E., Moore M. L.. ( 2012; ). Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. . J Virol 86:, 13016–13024. [CrossRef] [PubMed]
    [Google Scholar]
  18. Salk J., Salk D.. ( 1977; ). Control of influenza and poliomyelitis with killed virus vaccines. . Science 195:, 834–847. [CrossRef] [PubMed]
    [Google Scholar]
  19. Schulz O., Diebold S. S., Chen M., Näslund T. I., Nolte M. A., Alexopoulou L., Azuma Y. T., Flavell R. A., Liljeström P., Reis e Sousa C.. ( 2005; ). Toll-like receptor 3 promotes cross-priming to virus-infected cells. . Nature 433:, 887–892. [CrossRef] [PubMed]
    [Google Scholar]
  20. Singh S. R., Dennis V. A., Carter C. L., Pillai S. R., Jefferson A., Sahi S. V., Moore E. G.. ( 2007; ). Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. . Vaccine 25:, 6211–6223. [CrossRef] [PubMed]
    [Google Scholar]
  21. Tamura S., Ito Y., Asanuma H., Hirabayashi Y., Suzuki Y., Nagamine T., Aizawa C., Kurata T.. ( 1992; ). Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. . J Immunol 149:, 981–988.[PubMed]
    [Google Scholar]
  22. Vermaelen K. Y., Carro-Muino I., Lambrecht B. N., Pauwels R. A.. ( 2001; ). Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. . J Exp Med 193:, 51–60. [CrossRef] [PubMed]
    [Google Scholar]
  23. Watt P. J., Robinson B. S., Pringle C. R., Tyrrell D. A. J.. ( 1990; ). Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. . Vaccine 8:, 231–236. [CrossRef] [PubMed]
    [Google Scholar]
  24. Wherry E. J., Teichgräber V., Becker T. C., Masopust D., Kaech S. M., Antia R., von Andrian U. H., Ahmed R.. ( 2003; ). Lineage relationship and protective immunity of memory CD8 T cell subsets. . Nat Immunol 4:, 225–234. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.058461-0
Loading
/content/journal/jgv/10.1099/vir.0.058461-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error